BACKGROUND: The prognosis of Ewing tumor (ET) patients has significantly improved to cure rates approximating 70%. The prognosis in relapse, however, is poor. Promising response rates have recently been reported for the combination of topotecan (TOPO) and cyclophosphamide (CYC) encouraging wider application of this combination in patients with relapsed ETs. This report summarizes the experience of patients treated with TOPO/CYC for recurrent or refractory disease within the German ET trials. PROCEDURE: Fifty-four patients aged 3.2-49.5 (median: 17.4) years received TOPO (0.75 mg/m2/day, days 1-5) and CYC (250 mg/m2/day, days 1-5) following first (40) or second (6) relapse or progression under first-line therapy (8). RESULTS: A median of 3 (range: 1-11) TOPO/CYC courses were given. Sixteen patients (32.6%) showed partial response (PR), 13/49 (26.5%) had stable disease (SD), 14/49 (28.6%) progressed, 2/49 (4.1%) showed a mixed response (MR). In 4 patients response was not documented, 5/54 patients with complete initial resection at the diagnosis of relapse were excluded from the response analysis. At completion of relapse therapy, 24/54 patients had entered complete (19) or partial (5) remission, 2 had SD, 26 showed progression, information was unavailable in 2 patients. Of the 19 relapse patients achieving complete response (CR), 10 maintained remission (52.6%). At the time of evaluation, after a median follow-up for survivors of 23.1 (range: 7.8-59.8) months from the event prompting TOPO/CYC treatment, 14/54 patients (25.9%) were in continuous complete (13) or partial (1) remission. Overall survival (OAS) after 1 year was 0.61 (95%-CI 0.47-0.74). CONCLUSION: TOPO/CYC is active in relapsed ETs and warrants further evaluation. (c) 2006 Wiley-Liss, Inc.
BACKGROUND: The prognosis of Ewing tumor (ET) patients has significantly improved to cure rates approximating 70%. The prognosis in relapse, however, is poor. Promising response rates have recently been reported for the combination of topotecan (TOPO) and cyclophosphamide (CYC) encouraging wider application of this combination in patients with relapsed ETs. This report summarizes the experience of patients treated with TOPO/CYC for recurrent or refractory disease within the German ET trials. PROCEDURE: Fifty-four patients aged 3.2-49.5 (median: 17.4) years received TOPO (0.75 mg/m2/day, days 1-5) and CYC (250 mg/m2/day, days 1-5) following first (40) or second (6) relapse or progression under first-line therapy (8). RESULTS: A median of 3 (range: 1-11) TOPO/CYC courses were given. Sixteen patients (32.6%) showed partial response (PR), 13/49 (26.5%) had stable disease (SD), 14/49 (28.6%) progressed, 2/49 (4.1%) showed a mixed response (MR). In 4 patients response was not documented, 5/54 patients with complete initial resection at the diagnosis of relapse were excluded from the response analysis. At completion of relapse therapy, 24/54 patients had entered complete (19) or partial (5) remission, 2 had SD, 26 showed progression, information was unavailable in 2 patients. Of the 19 relapse patients achieving complete response (CR), 10 maintained remission (52.6%). At the time of evaluation, after a median follow-up for survivors of 23.1 (range: 7.8-59.8) months from the event prompting TOPO/CYC treatment, 14/54 patients (25.9%) were in continuous complete (13) or partial (1) remission. Overall survival (OAS) after 1 year was 0.61 (95%-CI 0.47-0.74). CONCLUSION:TOPO/CYC is active in relapsed ETs and warrants further evaluation. (c) 2006 Wiley-Liss, Inc.
Authors: K A Kasow; C F Stewart; R C Barfield; N L Wright; C Li; D K Srivastava; W Leung; E M Horwitz; L C Bowman; R Handgretinger; G A Hale Journal: Bone Marrow Transplant Date: 2012-03-19 Impact factor: 5.483
Authors: Michael V Ortiz; Heather Magnan; Emily K Slotkin; Srikanth R Ambati; Alexander J Chou; Leonard H Wexler; Paul A Meyers; Michael F Walsh; Todd Heaton; Leonard N Girardi; Suzanne L Wolden; Anita P Price; Jennifer A Kennedy; Ahmet Zehir; Meera Hameed; Michael F Berger; Alex Kentsis; Neerav Shukla Journal: J Pediatr Hematol Oncol Date: 2017-11 Impact factor: 1.289
Authors: Mouna Kairouani; Maha Mokrim; Nawfel Mellas; Basma Khennoussi; Hind El M'rabti; Saber Boutayeb; Hassan Errihani Journal: Int J Surg Case Rep Date: 2012-02-28
Authors: Leo Mascarenhas; Judy L Felgenhauer; Mason C Bond; Doojduen Villaluna; Joseph Dominic Femino; Nadia N Laack; Sarangarajan Ranganathan; James Meyer; Richard B Womer; Richard Gorlick; Mark D Krailo; Neyssa Marina Journal: Pediatr Blood Cancer Date: 2015-11-18 Impact factor: 3.167
Authors: Vivek Subbiah; Pete Anderson; Alexander J Lazar; Emily Burdett; Kevin Raymond; Joseph A Ludwig Journal: Curr Treat Options Oncol Date: 2009-06-17